OTLK
Outlook Therapeutics, Inc.
Biotechnology
Market Cap$14M
5Y Perf.-98.9%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
OTLK vs REPL
Revenue, margins, valuation, and 5-year total return — side by side.
REPL
Replimune Group, Inc.
Biotechnology
Market Cap$266M
5Y Perf.-78.3%
OTLK vs REPL — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | OTLK | REPL |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $14M | $266M |
| Revenue (TTM) | $206K | $0.00 |
| Net Income (TTM) | $-103M | $-315M |
| Gross Margin | -5.9% | — |
| Operating Margin | -286.8% | — |
| Total Debt | $247.70B | $76M |
| Cash & Equiv. | $8.08T | $111M |
OTLK vs REPL — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
OTLK
REPL
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Outlook Therapeutic… (OTLK) | 100 | 1.1 | -98.9% |
| Replimune Group, In… (REPL) | 100 | 21.7 | -78.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: OTLK vs REPL
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: REPL leads in 3 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Outlook Therapeutics, Inc. is the stronger pick specifically for growth and revenue expansion and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
OTLK
Outlook Therapeutics, Inc.
The Growth Play
OTLK is the clearest fit if your priority is growth exposure.
- Rev growth 20.8%, EPS growth 55.9%
- 20.8% revenue growth vs REPL's -39.7%
- -0.0% ROA vs REPL's -94.4%
Best for: growth exposure
REPL
Replimune Group, Inc.
The Income Pick
REPL carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 0.83
- -78.0% 10Y total return vs OTLK's -100.0%
- Lower volatility, beta 0.83, Low D/E 18.3%, current ratio 7.95x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | OTLK | 20.8% revenue growth vs REPL's -39.7% |
| Quality / Margins | REPL | 2.4% margin vs OTLK's -500.5% |
| Stability / Safety | REPL | Beta 0.83 vs OTLK's 1.54 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | REPL | -53.4% vs OTLK's -84.7% |
| Efficiency (ROA) | OTLK | -0.0% ROA vs REPL's -94.4% |
OTLK vs REPL — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLREPLLAGGINGOTLK
OTLKOutlook Therapeutics,…
1leads
REPLReplimune Group, Inc.
4leads
6 Total Categories
CATEGORYLEADERvs OTLKMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
REPL1/1
Valuation MetricsMultiples, price ratios, and targets
REPL1/1
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
OTLK3/5
Total Returns1Y, 3Y, 5Y total returns with dividends
REPL6/6
Risk & VolatilityBeta, volatility, and downside exposure
REPL2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
REPL leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
OTLK and REPL operate at a comparable scale, with $205,535 and $0 in trailing revenue.
| Metric | OTLKOutlook Therapeut… | REPLReplimune Group, … |
|---|---|---|
| RevenueTrailing 12 months | $205,535 | $0 |
| EBITDAEarnings before interest/tax | -$59M | -$323M |
| Net IncomeAfter-tax profit | -$103M | -$315M |
| Free Cash FlowCash after capex | -$14.94T | -$283M |
| Gross MarginGross profit ÷ Revenue | -5.9% | — |
| Operating MarginEBIT ÷ Revenue | -286.8% | — |
| Net MarginNet income ÷ Revenue | -500.5% | — |
| FCF MarginFCF ÷ Revenue | -999999.0% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | -152.8% | +2.5% |
REPL leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
REPL leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | OTLKOutlook Therapeut… | REPLReplimune Group, … |
|---|---|---|
| Market CapShares × price | $14M | $266M |
| Enterprise ValueMkt cap + debt − cash | -$7.84T | $231M |
| Trailing P/EPrice ÷ TTM EPS | -0.12x | -1.09x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 9.85x | — |
| Price / BookPrice ÷ Book value/share | — | 0.65x |
| Price / FCFMarket cap ÷ FCF | — | — |
REPL leads this category, winning 1 of 1 comparable metric.
Profitability & Efficiency
OTLK leads this category, winning 3 of 5 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), OTLK scores 4/9 vs REPL's 2/9, reflecting mixed financial health.
| Metric | OTLKOutlook Therapeut… | REPLReplimune Group, … |
|---|---|---|
| ROE (TTM)Return on equity | — | -149.5% |
| ROA (TTM)Return on assets | -0.0% | -94.4% |
| ROICReturn on invested capital | — | -51.9% |
| ROCEReturn on capital employed | — | -55.9% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 2 |
| Debt / EquityFinancial leverage | — | 0.18x |
| Net DebtTotal debt minus cash | -$7.84T | -$35M |
| Cash & Equiv.Liquid assets | $8.08T | $111M |
| Total DebtShort + long-term debt | $247.7B | $76M |
| Interest CoverageEBIT ÷ Interest expense | -182.41x | -48.62x |
OTLK leads this category, winning 3 of 5 comparable metrics.
Total Returns (Dividends Reinvested)
REPL leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in REPL five years ago would be worth $932 today (with dividends reinvested), compared to $50 for OTLK. Over the past 12 months, REPL leads with a -53.4% total return vs OTLK's -84.7%. The 3-year compound annual growth rate (CAGR) favors REPL at -43.0% vs OTLK's -78.9% — a key indicator of consistent wealth creation.
| Metric | OTLKOutlook Therapeut… | REPLReplimune Group, … |
|---|---|---|
| YTD ReturnYear-to-date | -67.3% | -62.5% |
| 1-Year ReturnPast 12 months | -84.7% | -53.4% |
| 3-Year ReturnCumulative with dividends | -99.1% | -81.5% |
| 5-Year ReturnCumulative with dividends | -99.5% | -90.7% |
| 10-Year ReturnCumulative with dividends | -100.0% | -78.0% |
| CAGR (3Y)Annualised 3-year return | -78.9% | -43.0% |
REPL leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
REPL leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
REPL is the less volatile stock with a 0.83 beta — it tends to amplify market swings less than OTLK's 1.54 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. REPL currently trades 25.2% from its 52-week high vs OTLK's 6.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | OTLKOutlook Therapeut… | REPLReplimune Group, … |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.47x | 0.80x |
| 52-Week HighHighest price in past year | $3.39 | $13.24 |
| 52-Week LowLowest price in past year | $0.16 | $1.50 |
| % of 52W HighCurrent price vs 52-week peak | +6.4% | +25.2% |
| RSI (14)Momentum oscillator 0–100 | 40.7 | 46.3 |
| Avg Volume (50D)Average daily shares traded | 4.0M | 5.6M |
REPL leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | OTLKOutlook Therapeut… | REPLReplimune Group, … |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $12.50 |
| # AnalystsCovering analysts | — | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 2 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
REPL leads in 4 of 6 categories (Income & Cash Flow, Valuation Metrics). OTLK leads in 1 (Profitability & Efficiency).
Best OverallReplimune Group, Inc. (REPL)Leads 4 of 6 categories
Loading custom metrics...
OTLK vs REPL: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is OTLK or REPL a better buy right now?
Analysts rate Replimune Group, Inc.
(REPL) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — OTLK or REPL?
Over the past 5 years, Replimune Group, Inc.
(REPL) delivered a total return of -90. 7%, compared to -99. 5% for Outlook Therapeutics, Inc. (OTLK). Over 10 years, the gap is even starker: REPL returned -73. 2% versus OTLK's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — OTLK or REPL?
By beta (market sensitivity over 5 years), Replimune Group, Inc.
(REPL) is the lower-risk stock at 0. 80β versus Outlook Therapeutics, Inc. 's 1. 47β — meaning OTLK is approximately 83% more volatile than REPL relative to the S&P 500.
04Which is growing faster — OTLK or REPL?
On earnings-per-share growth, the picture is similar: Outlook Therapeutics, Inc.
grew EPS 55. 9% year-over-year, compared to 5. 2% for Replimune Group, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — OTLK or REPL?
Replimune Group, Inc.
(REPL) is the more profitable company, earning 0. 0% net margin versus -44. 2% for Outlook Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: REPL leads at 0. 0% versus -47. 4% for OTLK. At the gross margin level — before operating expenses — OTLK leads at 46. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — OTLK or REPL?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is OTLK or REPL better for a retirement portfolio?
For long-horizon retirement investors, Replimune Group, Inc.
(REPL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 80)). Both have compounded well over 10 years (REPL: -73. 2%, OTLK: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between OTLK and REPL?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.